摘要
目的探讨黄芪甲苷(Astragaloside-Ⅳ,ASIV)对乳腺癌干细胞(breast cancer stem cells,BCSCs)化疗敏感性的影响。方法体外培养乳腺癌SUM159细胞,通过悬浮培养诱导SUM159干细胞。首先鉴定SUM159-CSCs干性,流式术检测CD44+/CD24-细胞群比例,观察贴壁再分化及球囊形成情况,其次检测SUM159-CSCs对紫杉醇(PTX)的耐药情况,CCK8试验检测细胞活力,流式细胞术检测细胞凋亡情况,3D球囊试验检测细胞成球活力;最后将SUM159-CSCs分为对照组、ASIV组、PTX组、ASIV联合PTX组,CCK8试验检测细胞活力,流式细胞术检测细胞凋亡情况,3D球囊试验检测细胞成球活力,Western bloting检测细胞中凋亡蛋白Bax和Bcl-2的表达水平。结果SUM159CSCs对PTX治疗抵抗性高于SUM159(P<0.05);ASIV联合PTX组明显抑制SUM159-CSCs细胞活力、增殖及球囊活力,Bax蛋白表达水平显著上调,Bcl-2蛋白表达水平显著下调。结论黄芪甲苷通过抑制肿瘤干细胞的增殖及促进细胞凋亡增强紫杉醇治疗的敏感性。
Objective To investigate the effect of astragaloside-Ⅳ(ASIV)on chemotherapy sensitivity of breast cancer stem cells(BCSCs).Methods Breast cancer SUM159 cells were cultured in vitro and SUM159 stem cells were induced by suspension culture.During the experiment,the stem of SUM159-CSCs was identified firstly by the proportion of CD44+/CD24-cell group detected by flow cytometry,and by the re-differentiation and balloon formation.Secondly,the drug resistance of SUM159-CSCs to paclitaxel(PTX)was observed:the cell viability was detected by CCK8 test,the apoptosis was detected with flow cytometry,cell ball-forming activity was detected by 3D balloon test.Finally,SUM159-CSCs was divided into control group,ASIV group,PTX group and ASIV+PTX group.And then cell viability was detected by CCK8 test,apoptosis was detected by flow cytometry,cell ball-forming activity was detected by 3D balloon test,and the expression of apoptotic protein Bax and Bcl-2 was detected by Western blotting method.Results The resistance of SUM159-CSCs to PTX was higher than that of SUM159(P<0.05).ASIV combined with PTX significantly inhibited the viability,proliferation and balloon viability of SUM159-CSCs cells,the expression of Bax was significantly up-regulated and the expression of Bcl-2 was significantly down-regulated.Conclusion ASIV can enhance the sensitivity of paclitaxel therapy by inhibiting the proliferation of tumor stem cells and promoting apoptosis.
作者
谢海媚
李华超
陈前军
XIE Hai-mei;LI Hua-chao;CHEN Qian-jun(Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou 510120 Guangdong,China)
出处
《中医肿瘤学杂志》
2022年第5期43-49,共7页
Journal of Oncology in Chinese Medicine
基金
国家自然科学基金(编号:81974571)。
关键词
黄芪甲苷
乳腺癌
肿瘤干细胞
化疗敏感性
astragaloside-Ⅳ
breast cancer
cancer stem cells
chemotherapy sensitivity
